9 September 2023 in Acta Biomaterialia
Biodegradable polymer-based therapeutics have recently become essential drug delivery biomaterials for various bioactive compounds. Biodegradable and biocompatible polymer-based biomaterials fulfill the requirements of these therapeutics because they enable to obtain polymer biomaterials with optimized blood circulation, pharmacokinetics, biodegradability, and renal excretion. Herein, we describe an adaptable polymerization platform employed for the synthesis of long-circulating, stimulus-sensitive and biodegradable biomaterials, therapeutics, or theranostics. Four chain transfer agents (CTA) were designed and successfully synthesized for the reversible addition-fragmentation chain transfer polymerization, allowing the straightforward synthesis of hydrolytically biodegradable structures of block copolymers-based biomaterials. The controlled polymerization using the CTAs enables controlling the half-life of the hydrolytic degradation of polymer precursors in a wide range from 5 h to 21 days. Moreover, the antitumor drug pirarubicin (THP) was successfully conjugated to the polymer biomaterials via a pH-sensitive hydrazone bond for in vitro and in vivo experiments. Polymer conjugates demonstrated superior antitumor efficacy compared to basic linear polymer-based conjugates. Notably, the biodegradable systems, even though those with degradation in the order of hours were selected, increased the half-life of THP in the bloodstream almost two-fold. Indeed, the presented platform design enables the main chain-end specific attachment of targeting ligands or diagnostic molecules. The adaptable polymerization platform design allows tuning of the biodegradability rate, stimuli-sensitive drug bonding, and optimized pharmacokinetics to increase the therapy outcome and system targeting, thus allowing the preparation of targeted or theranostic polymer conjugates. STATEMENT OF SIGNIFICANCE: Biodegradable and biocompatible polymer-based biomaterials are recognized as potential future bioactive nanomedicines. To advance the development of such biomaterials, we developed polymerization platforms utilizing tailored chain transfer agents allowing the straightforward synthesis of hydrolytically degradable polymer biomaterials with tuned biodegradability from hours to several days. The platform allows for the synthesis of long-circulating, stimulus-sensitive and biodegradable biomaterial serving as drug carriers or theranostics. The therapeutic potential was validated by preparation of polymer biomaterials containing pirarubicin, anticancer drug, bound via pH sensitive bond and by showing prolonged blood circulation and increased antitumor activity while keeping the drug side effects low. This work paves the way for future development of biodegradable polymer biomaterials with advanced properties in drug delivery.
8 January 2024 in European Polymer Journal
1 August 2022 in Nanomedicine
Background: Exosomes are extracellular vesicles with the ability to encapsulate bioactive molecules, such as therapeutics. This study identified a new exosome mediated route of doxorubicin and poly... Graphical abstract Cancerostatics delivered to the tumor site via the bloodstream facilitated by the enhanced permeability and retention effect are taken up by peripheral tumor cells. Inside the mu... Plain language summary Background: In cancer treatment, low-molecular-weight drugs (e.g., doxorubicin [DOX]) with a broad spectrum of side effects are commonly used. Through their conjugation with ...
21 November 2025 in Polymer Chemistry
Water-soluble polymers are extensively studied materials in the field of biomedical chemistry research.
1 March 2026 in ACS Applied Polymer Materials
GGGabriela S. García-Briones
Gabriela S. García-Briones
+4
Synthetic polycations are key components for engineering polyelectrolyte complexes with wide-ranging biomedical potential. However, the high cytotoxicity of fully charged polycations remains a major limitation for clinical applications. To address this challenge, we report on polycations derived from the cationic monomer 2-(N,N-dimethylaminoethyl) acrylate (DMAEA), which gradually loses charge through hydrolysis, thereby reducing their charge density over time. The overall charge fraction (from 100% to 20%) was further controlled through copolymerization with the neutral comonomer 2-hydroxyethyl acrylate (HEA). The selected conditions of reversible addition–fragmentation chain transfer (RAFT) copolymerization, specifically protonation of DMAEA with trifluoroacetic acid to mask its tertiary amino groups, enabled a precise control over the characteristics of the copolymers (termed D/H) up to 75% conversions, with close agreement between theoretical and experimental molecular weights up to 100 000 g/mol, consistently low dispersities (<1.2), and an excellent match between the theoretical and actual copolymer compositions. Hydrolysis studies at pH 7.4 showed that increasing the HEA content in D/H copolymers from 20 to 50 mol % led to only a 10% increase in the hydrolysis over 3 weeks. Isothermal titration calorimetry analysis demonstrated that all copolymers retained their ability to complex with heparin, with binding strength comparable to that of commonly used polycations. Importantly, the cytotoxicity of D/H copolymers toward human umbilical vein endothelial cells (HUVECs) decreased with increasing HEA content, reaching more than 80% cell viability at a relatively high concentration of 30 μg/mL. These findings demonstrate that D/H copolymers combine precise structural control with reduced cytotoxicity, making them promising candidates for biomedical polyelectrolyte platforms.
17 March 2026 in Biomaterials Science
The increasing prevalence of multidrug-resistant bacteria necessitates innovative antibiotic strategies beyond the discovery of new active compounds. Here, we report N-(2-hydroxypropyl)methacrylamide (HPMA)-based polymer–ciprofloxacin conjugates combining controlled drug release with siderophore-mediated targeting via a deferoxamine–Fe3+ (DFX–Fe) complex. The conjugates differed in linker type (non-cleavable amide vs. reductively cleavable disulfide) and in the presence of the DFX–Fe targeting unit. Non-cleavable conjugates showed strongly reduced antibacterial activity, whereas disulfide-linked systems enabled the release of chemically intact and biologically active ciprofloxacin under reducing conditions. DFX–Fe targeting significantly enhanced the efficacy of non-cleavable conjugates, while modulating drug release kinetics in cleavable systems due to the redox activity of Fe3+. Antibacterial activity against Escherichia coli and Staphylococcus aureus strongly depended on the conjugate structure and bacterial species. Importantly, in a macrophage intracellular infection model, stimuli-responsive conjugates exhibited high bactericidal activity, reducing intracellular bacteria to below 1% at a 2× MIC concentration. This observation indicates the great potential of these nanotherapeutics in the treatment of challenging bacterial infections. All systems showed good biocompatibility toward human fibroblasts. Overall, this study highlights the critical roles of linker cleavability and siderophore-mediated targeting in the design of polymeric antibiotics for intracellular bacterial infections.